Akero's drug for fatty liver disease misses main trial goal

Akero Therapeutics

10/10/2023 12:15

Oct 10 (Reuters) - Akero Therapeutics  AKRO.O  said on
Tuesday its drug to treat a type of fatty liver disease showed
improvement in patients in a mid-stage trial, but the data
showed that the results were not statistically significant.

 (Reporting by Leroy Leo in Bengaluru)
 ((Leroy.Dsouza@thomsonreuters.com ; https://twitter.com/LeroyLeo7;))